Wednesday , December 13 2017
Home / Letter From The Editor / May 14, 2016

May 14, 2016


Over the past 4 months, we have had over 22 items looking at the cardiovascular effects of diabetes drugs. Some of the items were focused on the increased risk of cardiovascular events; others were focused on the benefits in patients to either prevent or help reduce cv events; and a third group of items look at diabetes drugs that have been declared to not have negative effects. One of the things that ring true in all these articles is the move from a class effect to an individual drug effect. This movement seems to be based on each manufacturer selecting a result and focusing on a study to show that the outcome is actually occurring.
This week we look at a study that affirms sitagliptin does not increase heart failure risk for patients with type 2 diabetes, as well as a study on a new GLP-1 analogue and how it appears to affect CV risk.

Announcements: Sunday, May 8, 7PM ET

From”Joy Pape RN, CDE answers your diabetes questions from the dLife mail; Michel Nischan prepares a delicious zucchini pancake; dLife revisits Pastor and CDE Jeannette Jordan; and travel tips to get you better prepared for traveling with diabetes.” Sundays live online at at 7 PM ET, 6 PM CT, and 4 PM PT. Keep up on the latest dLife news at


We can make a difference!


Dave Joffe, Editor-in-chief